CClinicalTrials.gg
Sign In
CompletedNCT01675700Updated Aug 30, 2012

Topical Nitrates for Myofascial Trigger Points

An interventional study of Nitroglycerin patch in Myofascial Trigger Points, sponsored by GF Strong Rehabilitation Centre. Completed. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-08-30.

Sponsored by GF Strong Rehabilitation Centre · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
19 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether a topical nitroglycerine patch applied daily over a trapezius trigger point can improve patients' symptoms.

If there is improvement, this open label study will help determine the degree of improvement and contribute to the design of a larger double blind placebo controlled trial.

We would consider moving forward to a large randomized trial if:

  • The intervention is acceptable to patients (>= 70%) and
  • Compliance is satisfactory (>=80%) and
  • We find preliminary evidence of efficacy, i.e. average reduction in pain of 20mm on the VAS.
02

Conditions studied

  • Myofascial Trigger Points

Keywords

  • Myofascial pain
  • Trigger point
  • Nitroglycerin
03

In context

Lead sponsor

This is the only study on the registry with GF Strong Rehabilitation Centre as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Inclusion criteria include age between 19 and 65 years old, myofascial pain lasting at least 6 months, and a myofascial trigger point point in the trapezius muscle.

Exclusion criteria

Exclusion Criteria:

  • Our exclusion criteria include symptomatic disc herniation, symptomatic cervical osteoarthritis, systemic infection, malignancy, collapsed vertebra, thoracic outlet syndrome, temporomandibular joint dysfunction, collagen-vascular disease, or brachial plexopathy. Patients with ongoing litigation regarding their symptoms are not eligible for this study. Also excluded are patients with underlying cardiac disease, hypotension, or medical conditions that may not allow them to tolerate the use of vasodilators, and those who use phosphodiesterase inhibitors.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Myofascial trigger point

    Patients diagnosed with myofascial trigger points who will receive a nitroglycerin patch over the trigger point.

    Drug: Nitroglycerin patch

Interventions

  • DrugNitroglycerin patch

    Nitroglycerin 0.1 mg/hr patch

    Also known as: Nitro-Dur 0.1

06

What researchers measure

Primary outcomes

  1. Pain at the time of clinic visit and over the previous week as measured by a Visual Analog Scale, VAS, for pain and a pressure algometer measurement to obtain pressure pain thresholds over the patients trigger point.

    Time frame: 1 month

Secondary outcomes

  1. As another secondary outcome we will ask the participants whether the benefits of the treatment are good enough that they would continue using the nitroglycerin patch. This will be a yes or no response.

    Time frame: 1 month

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01675700
Lead sponsor
GF Strong Rehabilitation Centre
Responsible party
Anibal Bohorquez (Medical Resident, GF Strong Rehabilitation Centre) — Principal investigator
First posted
Aug 30, 2012
Start date
Jan 2009
Primary completion
Jul 2009
Completion
Dec 2009
Last update
Aug 30, 2012

Study contacts

Hubert A Anton, MD
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion